LPC
PCRX icon

Lion Point Capital’s Pacira BioSciences PCRX Stock Holding History

Lion Point Capital’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$342K Hold
13,500
– – 1.64% 23
2026
Q1 		$305K Hold
13,500
– – 1.82% 23
2025
Q4 		$349K Buy
+13,500
New +$321K 1.81% 27

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lion Point Capital's PCRX Position: Q2 2026 in Review

Lion Point Capital held its Pacira BioSciences (PCRX) position steady in Q2 2026 at 13,500 shares worth $342K. The position accounts for 1.64% of the portfolio, ranked #23.

Lion Point Capital first reported a position in PCRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $349K in Q4 2025. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Lion Point Capital held 13,500 shares of Pacira BioSciences worth $342K as of Q2 2026.
  • Lion Point Capital left its Pacira BioSciences share count unchanged in Q2 2026.
  • Pacira BioSciences made up 1.64% of Lion Point Capital's portfolio in Q2 2026, its #23 holding.
  • Lion Point Capital first reported a position in Pacira BioSciences in Q4 2025 and has held it in 3 quarters since.
  • Lion Point Capital's Pacira BioSciences position peaked at $349K in Q4 2025.
  • 254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Lion Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.